Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Authors

Robert D Morgan, Catharine Porter, Cong Zhou, Rebecca Kristeleit, Sudha Desai, Ignacio Vazquez, Angela George, Gemma Eminowicz, Axel Walther, Adrian Franklin, Azmat H Sadozye, Andrew Hughes, Louise Hanna, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Ann White, Angela C Casbard, Alys Humphrys, Jennifer B Swettenham, Lisette S Nixon, Richard Adams, Ruby Ray, Elena Brogden, Wendy E Powell, Joanna Canham, Tracy M Cox, Monica Narasimham, Helen Lowe, Leah Ensell, Mohammed Zubair, Karen Morris, Molly Glenister-Doyle, Ariadna Fuertes Gassio, Derrick Morgan, Dylan Broughton, Margherita Carucci, Phillip J Monaghan, Jonathan Tugwood, Richard J Edmondson, Caroline Dive, Gordon C Jayson, Andrew R Clamp

Published in

EClinicalMedicine. Volume 96. Pages 104012. Epub Jun 16, 2026.

Abstract

Patients with advanced or recurrent endometrial cancer have poor survival outcomes because effective treatment options remain limited. We investigated the efficacy and safety of cediranib plus weekly paclitaxel or olaparib versus weekly paclitaxel alone after prior platinum-based chemotherapy.
COPELIA was an open-label, randomised, phase 2 trial undertaken at 15 centres in the United Kingdom. Eligible participants were aged 16 years or older with histologically confirmed endometrial cancer, Eastern Cooperative Oncology Group performance status 0-1, a life expectancy greater than 16 weeks, and at least one previous line of platinum-based chemotherapy. Patients were randomly assigned to paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle (arm 1, control); cediranib 20 mg daily plus the same paclitaxel schedule (arm 2, experimental); or cediranib 20 mg daily plus olaparib 300 mg twice daily (arm 3, experimental). Up to six cycles of paclitaxel were permitted. Patients in arm 2 with a Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 complete or partial response, or stable disease, after paclitaxel plus cediranib continued cediranib monotherapy. The primary endpoint was the proportion of patients free from RECIST-defined progression or death at 3 months (PFS at 3 months). Secondary endpoints included RECIST response, PFS at 6 months, median PFS, median overall survival (OS), safety, and quality of life. Translational analyses assessed vascular response, defined as a reduction of 5% or more in plasma Tie2 within 9 weeks of treatment initiation. The trial was registered with EudraCT (2016-004617-28), ISRCTN (16320634), and ClinicalTrials.gov (NCT03570437).
Between May 1, 2018, and January 11, 2022, 124 patients were enrolled and randomised to arm 1 (n = 41), arm 2 (n = 41), or arm 3 (n = 42). Median follow-up in arms 1, 2, and 3 was 34.4 months (interquartile range [IQR] 11.6-37.6), 26.3 months (11.8-not evaluable), and 23.7 months (15.0-not evaluable), respectively. PFS at 3 months was significantly higher in arm 2 than in arm 1 (73.2% versus 48.8%; adjusted odds ratio [aOR] 3.2, lower limit of one-sided 80% confidence interval [CI] 2.1; p = 0.01). RECIST response was also higher in arm 2 versus arm 1 (56.4% versus 28.2%; aOR 5.7, 95% CI 1.8-17.6; p < 0.001). No differences were observed between arm 3 and arm 1 for PFS at 3 months (aOR 1.0, lower limit of one-sided 80% CI 0.71; p = 0.46) or RECIST response (aOR 0.8, 95% CI 0.3-2.6; p = 0.73). Median OS was 12.8 months (95% CI 7.3-16.8) in arm 1, 18.1 months (9.5-26.4; log-rank p = 0.42 versus arm 1) in arm 2, and 13.9 months (11.2-18.3; log-rank p = 0.86 versus arm 1) in arm 3. There was no difference in PFS at 6 months and median PFS between arm 1 and arm 2 or arm 3. Grade 3 adverse events occurring in ≥10% of patients in arm 2 included hypertension (15%), neutropenia (12%), and diarrhoea (10%). Quality-of-life differences favoured arm 1 over arm 2 for diarrhoea and gastrointestinal symptoms (p < 0.001). In multivariable analyses, cediranib-treated patients who achieved a Tie2-defined vascular response had significantly improved PFS (hazard ratio 0.54, 95% CI 0.33-0.88; p = 0.014).
Paclitaxel plus cediranib improved 3-month PFS and RECIST response compared with paclitaxel alone in advanced or recurrent endometrial cancer. However, this effect diminished over time; with no difference in PFS observed at 6 months, nor median PFS or median OS. Plasma Tie2 identified cediranib-treated patients with improved PFS. Further evaluation of paclitaxel plus cediranib in patients previously treated with platinum-based chemotherapy and immunotherapy is warranted, ideally incorporating plasma Tie2 as a response biomarker to guide treatment continuation.
AstraZeneca.

PMID:
42339309
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.